Dogwood Therapeutics, Inc.
DWTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.03 | 0.01 | 0.30 |
| FCF Yield | -343.50% | -45.10% | -438.95% | -36.82% |
| EV / EBITDA | -0.27 | -1.37 | 0.36 | -1.83 |
| Quality | ||||
| ROIC | -13.40% | -143.08% | -168.09% | -107.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 0.92 | 0.94 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -80.49% | 57.53% | 26.91% | -302.79% |
| Safety | ||||
| Net Debt / EBITDA | -0.06 | 0.61 | 0.57 | 0.90 |
| Interest Coverage | -132.63 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -36,922.79 | 0.00 | 0.00 | 0.00 |